Solid Biosciences Inc. (SLDB)
| Market Cap | 615.47M +31.5% |
| Revenue (ttm) | n/a |
| Net Income | -207.10M |
| EPS | -1.87 |
| Shares Out | 107.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,033,369 |
| Open | 5.55 |
| Previous Close | 5.47 |
| Day's Range | 5.39 - 5.84 |
| 52-Week Range | 3.79 - 11.45 |
| Beta | 2.47 |
| Analysts | Strong Buy |
| Price Target | 18.71 (+225.96%) |
| Est. Earnings | Nov 2, 2026 |
About SLDB
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for SLDB stock is "Strong Buy." The 12-month stock price target is $18.71, which is an increase of 225.96% from the latest price.
News
Solid Biosciences initiated with a Buy at UBS
UBS analyst Joon Lee initiated coverage of Solid Biosciences (SLDB) with a Buy rating and $20 price target The company’s lead drug is SGT-003 for Duchenne muscular dystrophy, and the…
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardia...
Solid Biosciences initiated with an Outperform at RBC Capital
RBC Capital analyst Luca Issi initiated coverage of Solid Biosciences (SLDB) with an Outperform rating and $18 price target The shares offer “fundamental upside” given its “differentiated approach” fo...
Solid Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is advancing AAV gene therapies for DMD and FA, prioritizing these programs with novel constructs and delivery platforms. Key FDA meetings and data readouts are expected in the next two quarters, with a strong cash position supporting operations into 2028.
Solid Biosciences Transcript: Citigroup’s Biopharma Back to School Summit 2026
Key regulatory meetings and data releases for DMD and FA are expected in the next six months, with the FDA reviewing one-year data from over 12 DMD patients and initial mFARS data from FA patients due in Q1. The company is advancing its phase III trials and expanding its next-generation capsid platform, supported by AI-driven data analysis and regulatory tools.
Solid Biosciences management to meet with Cantor
Meeting to be held in New York on September 15 hosted by Cantor.
Solid Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is advancing gene therapies for DMD and FA, with strong trial demand and a robust biomarker strategy. Novel delivery platforms and capsids drive efficacy and safety, while regulatory and clinical data updates are expected by early next year. FA program progress and European expansion are key growth drivers.
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscula...
Solid Biosciences price target raised to $26 from $16 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Solid Biosciences (SLDB) to $26 from $16 and keeps an Overweight rating on the shares. Solid Biosciences’ key catalyst is the YE26/early-27…
Solid Biosciences assumed with a Buy at Truist
Truist analyst Danielle Brill assumed coverage of Solid Biosciences (SLDB) with a Buy rating with a price target of $20, up from $16. SGT-003, the company’s lead gene therapy for…
Solid Biosciences reports Q2 EPS (38c), consensus (47c)
Bo Cumbo, President and CEO of Solid Biosciences (SLDB), stated: “Our progress in the first half of 2026 positions us for continued momentum as we approach multiple key clinical and…
Solid Biosciences files automatic mixed securities shelf
17:01 EDT Solid Biosciences (SLDB) files automatic mixed securities shelf
Solid Biosciences Quarterly report: Q2 2026
Solid Biosciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
Solid Biosciences Earnings release: Q2 2026
Solid Biosciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Solid Biosciences Transcript: AGM 2026
The meeting confirmed quorum, elected directors, ratified the auditor, and approved doubling authorized shares. All proposals passed, with final results to be filed in Form 8-K. No questions were raised by stockholders during the session.
Solid Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The pipeline features advanced gene therapies for Duchenne and Friedreich's ataxia, with strong safety and efficacy signals in ongoing trials. Unique transgene and capsid designs drive superior tissue targeting and biomarker improvements, while regulatory and commercial milestones are expected in 2024–2025.
Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Key programs in Duchenne and Friedreich's ataxia are advancing, with robust biomarker and safety data supporting clinical benefit. FDA feedback has shaped trial design and data analysis, with pivotal discussions and potential accelerated approval expected later this year.
Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Solid Biosciences (SLDB) to $25 from $20 and keeps a Buy rating on the shares. The firm views the company’s SGT-212 program…
Solid Biosciences price target lowered to $16 from $17 at Wedbush
Wedbush lowered the firm’s price target on Solid Biosciences (SLDB) to $16 from $17 and keeps an Outperform rating on the shares. Most important in the Q1 update from Solid…
Solid Biosciences price target raised to $18 from $17 at Piper Sandler
Piper Sandler analyst Biren Amin raised the firm’s price target on Solid Biosciences (SLDB) to $18 from $17 and keeps an Overweight rating on the shares. In Q1 financial results,…
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agenc...
Solid Biosciences Quarterly report: Q1 2026
Solid Biosciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
Solid Biosciences Earnings release: Q1 2026
Solid Biosciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Solid Biosciences doses part participant in IMPACT DUCHENNE study
Solid Biosciences (SLDB) announced that the first participant has been dosed in IMPACT DUCHENNE, the company’s multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial inves...
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global re...